[{"id":"9efaf1c1-aab7-4353-870f-d5480b4a1d72","acronym":"","url":"https://clinicaltrials.gov/study/NCT01787500","created_at":"2021-01-17T17:23:41.948Z","updated_at":"2024-07-02T16:35:13.928Z","phase":"Phase 1","brief_title":"Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01787500","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • RAS wild-type • BRAF positive","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • RAS wild-type • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Zelboraf (vemurafenib) • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/15/2013","start_date":" 02/15/2013","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-03-20"},{"id":"77e1b7f5-c1b9-4298-966a-c925677f0ef6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05984615","created_at":"2023-08-09T14:09:44.054Z","updated_at":"2024-07-02T16:35:40.518Z","phase":"","brief_title":"Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients","source_id_and_acronym":"NCT05984615","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" BRAF positive","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF positive"],"overall_status":"Completed","enrollment":" Enrollment 1961","initiation":"Initiation: 06/08/2022","start_date":" 06/08/2022","primary_txt":" Primary completion: 08/24/2022","primary_completion_date":" 08/24/2022","study_txt":" Completion: 08/24/2022","study_completion_date":" 08/24/2022","last_update_posted":"2023-08-09"},{"id":"4257f9d5-1726-4b59-9737-b7a9b738c651","acronym":"","url":"https://clinicaltrials.gov/study/NCT05892653","created_at":"2023-06-07T14:07:59.887Z","updated_at":"2024-07-02T16:35:42.214Z","phase":"Phase 1","brief_title":"A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors","source_id_and_acronym":"NCT05892653","lead_sponsor":"ABM Therapeutics Shanghai Company Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABM-1310"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 05/29/2028","primary_completion_date":" 05/29/2028","study_txt":" Completion: 05/29/2028","study_completion_date":" 05/29/2028","last_update_posted":"2023-07-24"},{"id":"3bf19aa7-554a-40df-9ef3-ee087e98a821","acronym":"","url":"https://clinicaltrials.gov/study/NCT05501912","created_at":"2022-08-16T12:57:46.458Z","updated_at":"2024-07-02T16:35:47.147Z","phase":"Phase 1","brief_title":"A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors","source_id_and_acronym":"NCT05501912","lead_sponsor":"ABM Therapeutics Shanghai Company Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABM-1310"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/24/2025","primary_completion_date":" 08/24/2025","study_txt":" Completion: 08/24/2025","study_completion_date":" 08/24/2025","last_update_posted":"2023-05-25"},{"id":"3c1b8319-6ad4-4665-beaf-1993b914633b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01164891","created_at":"2021-01-18T04:38:40.449Z","updated_at":"2024-07-02T16:35:51.434Z","phase":"Phase 1","brief_title":"A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01164891","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2023-04-05"},{"id":"54accd08-1a26-4357-b09a-9c2d8e7f781a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01904123","created_at":"2021-01-18T08:34:31.425Z","updated_at":"2024-07-02T16:36:14.851Z","phase":"Phase 1","brief_title":"STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain","source_id_and_acronym":"NCT01904123","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WP1066"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 03/16/2022","primary_completion_date":" 03/16/2022","study_txt":" Completion: 03/16/2022","study_completion_date":" 03/16/2022","last_update_posted":"2022-03-23"},{"id":"b85d6746-fd8e-4298-a996-7b00e3b2f86c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01910181","created_at":"2021-01-18T08:36:36.293Z","updated_at":"2024-07-02T16:36:59.278Z","phase":"Phase 1","brief_title":"A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT01910181","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 08/17/2013","start_date":" 08/17/2013","primary_txt":" Primary completion: 10/22/2013","primary_completion_date":" 10/22/2013","study_txt":" Completion: 04/20/2018","study_completion_date":" 04/20/2018","last_update_posted":"2019-05-29"},{"id":"fc15a184-24b8-4b65-99d3-1679e83c959d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00880321","created_at":"2021-01-17T17:41:21.817Z","updated_at":"2024-07-02T16:37:16.456Z","phase":"Phase 1","brief_title":"A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors","source_id_and_acronym":"NCT00880321","lead_sponsor":"GlaxoSmithKline","biomarkers":" CXCL8","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF positive","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tafinlar (dabrafenib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 06/04/2009","start_date":" 06/04/2009","primary_txt":" Primary completion: 03/25/2011","primary_completion_date":" 03/25/2011","study_txt":" Completion: 03/20/2012","study_completion_date":" 03/20/2012","last_update_posted":"2017-11-13"},{"id":"34b40a62-006a-47e4-ba22-47e249a547ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT01264380","created_at":"2021-01-18T05:06:15.503Z","updated_at":"2024-07-02T16:37:28.011Z","phase":"Phase 1","brief_title":"A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma","source_id_and_acronym":"NCT01264380","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2016-11-02"}]